Abstract
Many studies have reported the role of glutathione S-transferase Mu 1 (GST M1) polymorphism with ovary cancer risk, but the results remained controversial. To derive a more precise estimation of the relationship, a meta-analysis was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between GSTM1 polymorphism and ovary cancer risk. A total of 11 studies including 2709 cases and 3599 controls were also involved in this meta-analysis. When all the eligible studies were pooled into this meta-analysis, no significant association between ovary cancer risk and GSTM1 polymorphism was found (OR = 1.010, 95% CI = 0.911-1.121, P heterogeneity = 0.174, P = 0.848). Our meta-analysis supports that the GSTM1 polymorphism is not contributed to the risk of ovary cancer from currently available evidence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
